Clinical trials: Advanced Tumor
Squamous Cell Carcinoma of the Anal Canal
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
- Trial name
- NCT04472429
- Testing
- carboplatin, paclitaxel, retifanlimab
- Where
- 84 sites in United States, Australia and 11 more
- Volunteers
- 308 people
- Sponsor
- Incyte Corporation
Rectal Cancer
Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
The National Comprehensive Cancer Network (NCCN) guidelines recommend trimodality treatment for patients with middle and low LARC with neoadjuvant chemoradiotherapy (NA-CRT), surgical resection with TME, plus additional…
- Trial name
- NCT05274945
- Testing
- Radiotherapy, consolidation chemotherapy, TME or APR
- Where
- Egypt
- Volunteers
- 58 people
- Sponsor
- Alexandria University
Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST)
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
This trial is a prospective, randomized (1:1 ratio), multicenter, comparative and phase II study, conducted in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of imatinib (disease…
- Conditions
- Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor
- Trial name
- ATEZOGIST (NCT05152472)
- Testing
- Atezolizumab 1200 mg, Imatinib 400 MG
- Where
- 13 sites in France
- Volunteers
- 58 people
- Sponsor
- Centre Leon Berard
Advanced Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of E6201 in subjects with advanced solid tumors.
- Trial name
- NCT00794781
- Testing
- E6201
- Where
- 12 sites in United States
- Volunteers
- 55 people
- Sponsor
- Eisai Inc.
Breast Cancer
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
The purpose of this study is to assess the efficacy, safety and tolerability of 2 dosing regimens of BIIB021 in combination with exemestane in women whose HR+ breast cancer had progressed following treatment with a nonsteroidal…
- Trial name
- NCT01004081
- Testing
- BIIB021, exemestane (Aromasin)
- Where
- 34 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Biogen
Alveolar Soft Part Sarcoma, Leiomyosarcoma
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA.
- Conditions
- Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
- Trial name
- APROMISS (NCT03016819)
- Testing
- AL3818, Dacarbazine, Midazolam 2 mg for CYP3A4 phenotyping
- Where
- 24 sites in United States, China and 3 more
- Volunteers
- 325 people
- Sponsor
- Advenchen Laboratories, LLC
Advanced Solid Tumors, Glioblastoma
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma
- Trial name
- NCT02611024
- Testing
- Lurbinectedin, Irinotecan
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 316 people
- Sponsor
- PharmaMar
HER2-Negative Advanced Breast Cancer
A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer
This is a randomized, open-label, multicenter Phase Ⅲ clinical trial designed to evaluate the efficacy and safety of HB1801 versus Taxotere® in patients with HER2-negative advanced breast cancer.
- Trial name
- NCT07805135
- Testing
- HB1801, Docetaxel (Taxotere®)
- Volunteers
- 430 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumor Cancers, Medulloblastoma
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
- Trial name
- NCT00880308
- Testing
- LDE225
- Where
- 5 sites in United States, Spain and 2 more
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC
The primary objective is to assess the safety and efficacy of hypofractionated radiotherapy followed by hypo-boost combined with concurrent weekly chemotherapy in unresectable LA-NSCLC patients.
- Trial name
- NCT03900117
- Testing
- split-course radiotherapy, concurrent chemotherapy
- Where
- China
- Volunteers
- 77 people
- Sponsor
- Sun Yat-sen University
Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric
Clofarabine in Adult Patients With Advanced Solid Tumors
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment…
- Conditions
- Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult, Leukemia, Myelocytic, Acute, Pediatric
- Trial name
- NCT00125840
- Testing
- clofarabine (IV formulation)
- Where
- 2 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Carcinoma, Non-Small-Cell Lung
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with erlotinib, and to assess the pharmacokinetics of CS-7017 in combination with…
- Trial name
- NCT01199068
- Testing
- CS-7017, Erlotinib
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Advanced Cancer
A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
This trial will be conducted in three parts. Part A is a dose escalation trial followed by a dose confirmation trial in folate receptor (FR) 100% endometrial cancer participants.
- Trial name
- NCT01688791
- Testing
- Vintafolide, Carboplatin, Paclitaxel
- Volunteers
- 37 people
- Sponsor
- Endocyte
Lymphedema, Lymphedema of Face
A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema
To compare the effectiveness of an APCD to Usual Care in the management of lymphedema and fibrosis (LEF) in head and neck cancer (HNC) survivors.
- Conditions
- Lymphedema, Lymphedema of Face, Lymphedema, Secondary, Lymphedema Due to Radiation
- Trial name
- NCT04797390
- Testing
- Advanced Pneumatic Compression Device (APCD), Usual Care
- Where
- 10 sites in United States
- Volunteers
- 236 people
- Sponsor
- Tactile Medical
Gastric Cancer, Chemoradiation
Feasibility Trial of Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer
Because locally far-advanced gastric cancer combined with adjacent tissue invasion has a poor prognosis, some phase 2 and 3 clinical trials of neoadjuvant chemotherapy (NAC) are performed in Japan.
- Trial name
- NCT01381913
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Kagawa University
Pheochromocytoma, Paraganglioma
211At-MABG in Adults With Advanced Neuroendocrine Cancers
Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible…
- Conditions
- Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors, Medullary Thyroid Cancer
- Trial name
- NCT07661420
- Testing
- 1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pennsylvania
CDH17-positive Advanced Solid Tumors
Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Solid Tumors
This is a single-center, open-label, single-arm study to evaluate the safety and preliminary efficacy of anti-CDH17 CAR-T cells in patients with CDH17-positive advanced solid tumors.
- Trial name
- NCT06820424
- Testing
- Anti-CDH17 CAR-T cells infusion
- Where
- China
- Volunteers
- 30 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Head and Neck Squamous Cell Carcinoma
The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR
This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of de-escalation of postoperative radiotherapy in locally advanced head and neck squamous cell carcinoma with pathological complete…
- Trial name
- NCT05854823
- Testing
- dose-reduced radiotherapy
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Stage IIIB or IV Non-Small Cell Lung Cancer
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin
- Trial name
- NCT00473889
- Testing
- vorinostat, Comparator: paclitaxel, Comparator: carboplatin
- Volunteers
- 253 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
This is a single-center, open-label, non-randomized Phase I study of weekly Cabazitaxel with concurrent intensity modulated radiation therapy (IMRT) (A type of 3-dimensional radiation therapy that uses computer-generated images…
- Trial name
- NCT01420250
- Testing
- Cabazitaxel, Intensity Modulated Radiation Therapy (IMRT), Anti-Androgen Therapy: Bicalutamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.